Richard Brundage, Pharm.D., Ph.D.

Science Advisor, Principal Scientist II

Dick joined MetrumRG in September 2022 as a Science Advisor, Principal Scientist II. Dick has a meritorious career in pharmacometrics and is particularly well known as a professor at the University of Minnesota and Graduate Faculty of Experimental and Clinical Pharmacology, where he taught for over 20 years. Listed below are a few of the numerous, noteworthy publications by Dick. 

Jaber MM, Yaman B, Sarafoglou K, Brundage RC. Application of Deep Neural Networks as a Prescreening Tool to Assign Individualized Absorption Models in Pharmacokinetic Analysis. Pharmaceutics. 2021 May 26;13(6):797. doi: 10.3390/pharmaceutics13060797. PMID: 34073609
Jaber MM, Cheng S, Brundage RC. Evaluation of bias in weighted residual calculations when handling below the limit of quantification data using Beal’s M3 method. CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):275-278. doi: 10.1002/psp4.12616. PMID: 33951756
Al‐Kofahi M, Ahmed MA, Jaber MM, Tran TN, Willis BA, Zimmerman CL, Gonzalez‐Bolanos MT, Brundage RC, Sarafoglou K. An integrated PK‐PD model for cortisol and the 17‐hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. Br J Clin Pharmacol. 2020 1-13. PMID: 32652643
Flora DR, Rettie AE, Brundage RC, Tracy TS. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites. J Clin Pharmacol. 2017;57(3):382-93. PMID: 27539372

Recent publications by this scientist

Training the next generation of pharmacometric modelers: a multisector perspective

September 25, 2023

The demand for pharmacometricians has outpaced academic supply, with increasing investments in on-the-job training. Despite growth in academic programs, the expanding scope of pharmacometrics and emerging fields like machine learning pose challenges. Leading experts from diverse sectors offer recommendations for effectively training future pharmacometricians, ensuring their ability to navigate this evolving discipline.

Download PDF

Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia

July 25, 2023

The aim of this study was to quantify identifiable sources of variability, including key pharmacogenetic variants in oxypurinol pharmacokinetics and their pharmacodynamic effect on serum urate (SU).

Read Article

Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling

July 25, 2023

The goal of this simulation-estimation study was to investigate the extent to which PK and RUV model misspecification, errors in recording dosing and sampling times, and variability in drug content uniformity contribute to the estimated magnitude of RUV and PK parameter bias.

Read Article